Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics - Pip

1. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Aarkstore Enterprise specialize in providing online market business information on market research reports, books, magazines, conference booking at competitive prices, and strive to provide excellent and innovative service to our customers.

2. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics - Pipeline Assessment and Market Forecasts to 2019 • Date: 29 February 2012 • Pages: 63 • SummaryCompany, the industry analysis specialist, has released its new report, “Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics - Pipeline Assessment and Market Forecasts to 2019. The report is an essential source of information and analysis on the global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market. The report identifies the key trends shaping and driving the global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Company team of industry experts.ScopeThe report provides information on the key drivers and challenges of the Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market. Its scope includes - - Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019. - Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.- Analysis of the current and future competition in the seven key countries Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market. - Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications. - Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market.- Analysis of key recent licensing and partnership agreements in Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market

3. Clostridium difficile Infection (CDI) Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Reasons to buyThe report will enhance your decision making capability. It will allow you to - - Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline. - Develop business strategies by understanding the trends shaping and driving the global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market. - Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market in future. - Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. - Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. - Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. - What the next big thing in the global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market landscape? – Identify, understand and capitalize.

4. 1.1 List of Tables 51.2 List of Figures 62 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics - Introduction 72.1 Overview 72.2 Classification of Idiopathic Thrombocytopenic Purpura 72.3 Pathophysiology of Chronic Idiopathic Thrombocytopenic Purpura 82.4 Epidemiology 92.5 Clinical Symptoms 92.6 Diagnosis and Management of Idiopathic Thrombocytopenic Purpura 92.7 Treatment of Idiopathic Thrombocytopenic Purpura 112.8 GlobalData Pipeline Report Guidance 123 Idiopathic Thrombocytopenic Purpura Therapeutics - Market Characterization 133.1 Idiopathic Thrombocytopenic Purpura Therapeutics Market Size (2006-2011) - Global 133.2 Idiopathic Thrombocytopenic Purpura Therapeutics Market Forecast (2011-2019) - Global 143.3 Idiopathic Thrombocytopenic Purpura Therapeutics Market Size (2006-2011) - the US 153.4 Idiopathic Thrombocytopenic Purpura Therapeutics Market Forecast (2011-2019) - the US 163.5 Idiopathic Thrombocytopenic Purpura Therapeutics Market Size (2006-2011) - the UK 173.6 Idiopathic Thrombocytopenic Purpura Therapeutics Market Forecast (2011-2019) - the UK 183.7 Idiopathic Thrombocytopenic Purpura Therapeutics Market Size (2006-2011) - France 193.8 Idiopathic Thrombocytopenic Purpura Therapeutics Market Forecast (2011-2019) - France 203.9 Idiopathic Thrombocytopenic Purpura Therapeutics Market Size (2006-2011) - Germany 213.10 Idiopathic Thrombocytopenic Purpura Therapeutics Market Forecast (2011-2019) - Germany 223.11 Idiopathic Thrombocytopenic Purpura Therapeutics Market Size (2006-2011) - Italy 233.12 Idiopathic Thrombocytopenic Purpura Therapeutics Market Forecast (2011-2019) - Italy 243.13 Idiopathic Thrombocytopenic Purpura Therapeutics Market Size (2006-2011) - Spain 253.14 Idiopathic Thrombocytopenic Purpura Therapeutics Market Forecast (2011-2019) - Spain 263.15 Idiopathic Thrombocytopenic Purpura Therapeutics Market Size (2006-2011) - Japan 273.16 Idiopathic Thrombocytopenic Purpura Therapeutics Market Forecast (2011-2019) - Japan 283.16.1 Drivers for the Idiopathic Thrombocytopenic Purpura Therapeutics Market 293.16.2 Barriers for the Idiopathic Thrombocytopenic Purpura Therapeutics Market 293.17 Key Events Impacting the Future Market 303.18 Opportunity and Unmet Need 313.19 Key Takeaway 32

5. 4 Idiopathic Thrombocytopenic Purpura Therapeutics Market - Competitive Assessment 334.1 Overview 334.2 Strategic Competitor Assessment 334.3 Product Profiles for the Major Marketed Products in the Idiopathic Thrombocytopenic Purpura Therapeutics Market 344.3.1 Nplate (romiplostim) 344.3.2 Promacta/Revolade (eltrombopag) 344.4 Key Takeaway 355 Idiopathic Thrombocytopenic Purpura Therapeutics Market - Pipeline Assessment 365.1 Overview 365.1.1 Strategic Pipeline Assessment 365.2 Idiopathic Thrombocytopenic Purpura Therapeutics Pipeline Analysis - Pipeline by Clinical Phases of Development 365.2.1 ITP Therapeutics - Phase III Clinical Pipeline 365.2.2 Idiopathic Thrombocytopenic Purpura Therapeutics - Phase II Clinical Pipeline 375.2.3 Idiopathic Thrombocytopenic Purpura Therapeutics - Phase I/II Clinical Pipeline 375.2.4 Idiopathic Thrombocytopenic Purpura Therapeutics - Pre-Clinical Pipeline 375.3 Idiopathic Thrombocytopenic Purpura Therapeutics Market - Clinical Pipeline by Mechanism of Action 385.4 Idiopathic Thrombocytopenic Purpura Technology Trends Analytical Framework 395.5 Molecule Profile for Late-Stage Drugs under Clinical Development 405.5.1 IGIV3I 10% Grifols 405.5.2 Mabthera (rituximab) 415.6 Key Takeaway 416 Idiopathic Thrombocytopenic Purpura Therapeutics - Clinical Trials Mapping 426.1 Clinical Trials by Country 426.2 Clinical Trials by Phase 436.3 Clinical Trials by Trial Status 446.4 Overall Sponsors 456.5 Prominent Sponsors 466.6 Top Companies Participating in Idiopathic Thrombocytopenic Purpura Therapeutics Clinical Trials 47

6. 7 Idiopathic Thrombocytopenic Purpura Therapeutics - Strategic Assessment 487.1 Future Market Competition Scenario 488 Idiopathic Thrombocytopenic Purpura Therapeutics - Future Players 498.1 Introduction 498.2 Company Profiles 508.2.1 F. Hoffmann-La Roche 508.2.2 GrifolsBiologicals Inc. 518.2.3 Amgen Inc. 518.2.4 GlaxoSmithKline plc 538.2.5 Other Companies in the Idiopathic Thrombocytopenic Purpura Therapeutics Market, 2011 559 Idiopathic Thrombocytopenic Purpura Therapeutics - Licensing and Partnership Deals 5610 Idiopathic Thrombocytopenic Purpura Therapeutics - Appendix 5710.1 Definitions 5710.2 Acronyms 5710.3 Research Methodology 5810.3.1 Coverage 5810.3.2 Secondary Research 5810.3.3 Forecasting 5910.3.4 Primary Research 6110.3.5 Expert Panel Validation 6210.4 Contact Us 6210.5 Disclaimer 6210.6 Bibliography 62 

7. For more information, please visit: • http://www.aarkstore.com/reports/Idiopathic-Thrombocytopenic-Purpura-ITP-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2019-198832.htmlOr email us at contact@aarkstore.com or call +919272852585 • Related Reports • Vemurafenib - Comprehensive patent searchColesevelam - Comprehensive patent searchRifaximin - Comprehensive patent searchNevirapine - Comprehensive patent searchLiraglutide - Comprehensive patent searchVilazodone - Comprehensive patent searchHexylaminolevulinic Acid - Comprehensive patent searchTreprostinil - Comprehensive patent searchPatient Adherence, Communication and Engagement (PACE) - Increased Investment and Adoption of New Digital Tools Enable Key Stakeholder Collaborations and Encourage ComplianceExpress Scripts, Inc.: Pharmaceuticals and Healthcare Company Profile, SWOT and Financial Report

8. Contact Us Aarkstore Enterprise Tel : +912227453309 Mobile No:+08149852585 Email : contact@aarkstore.com Website : http://www.aarkstore.com Blog: http://www.emarketreports.com http://teju-aarkstoreenterprise.blogspot.in Follow us on twitter: http://twitter.com/aarkstoredotcom http://in.linkedin.com/in/aarkstore http://www.facebook.com/aarkstoreenterprise